Zenas BioPharma, Inc. (ZBIO)
NASDAQ: ZBIO · Real-Time Price · USD
7.84
-0.36 (-4.41%)
Mar 31, 2025, 2:00 PM EDT - Market open

Zenas BioPharma Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022
Period Ending
Dec '24 Dec '23 Dec '22
Net Income
-156.99-37.12-119.28
Depreciation & Amortization
0.140.110.08
Asset Writedown & Restructuring Costs
-101
Loss (Gain) From Sale of Investments
-0.6--
Stock-Based Compensation
10.823.50.74
Other Operating Activities
1.531.0343.85
Change in Accounts Payable
11.74-0.421.09
Change in Other Net Operating Assets
13.69-7.626.88
Operating Cash Flow
-119.67-30.53-65.65
Capital Expenditures
-0.13-0.02-0.2
Sale (Purchase) of Intangibles
---2
Investment in Securities
-30.42--
Investing Cash Flow
-30.55-0.02-2.2
Long-Term Debt Issued
-20-
Net Debt Issued (Repaid)
-20-
Issuance of Common Stock
240.910.12-
Other Financing Activities
-6.33--
Financing Cash Flow
412.9620.1259.39
Foreign Exchange Rate Adjustments
0.160.08-0.04
Net Cash Flow
262.89-10.35-8.5
Free Cash Flow
-119.81-30.55-65.85
Free Cash Flow Margin
-2396.10%-61.09%-
Free Cash Flow Per Share
-9.08-19.95-44.13
Levered Free Cash Flow
-60.01-17.64-
Unlevered Free Cash Flow
-60.01-17.64-
Change in Net Working Capital
-31.64.26-
Updated Mar 11, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q